Table 3.

Best overall response per RANO criteria

Best Overall Response n (%)	Galunisertib + Lomustine N = 79	Galunisertib N = 39	Placebo + Lomustine N = 40
Complete response (CR)	1 (1.3)	0	0
Partial response (PR)	0	2 (5.1)	0
Stable disease (SD)	16 (20.3)	10 (25.6)	12 (30.0)
Progressive disease (PD)	50 (63.3)	21 (53.8)	26 (65.0)
Unevaluable/no lesion measures post baseline	12 (15.2)	6 (15.4)	2 (5.0)
Number of clinical benefit responders (CR + PR + SD)	17 (21.5)	12 (30.8)	12 (30.0)

Abbreviation: RANO, Response Assessment in Neuro-oncology.

The denominator for response rates is the number of randomized patients per arm. All randomized patients had measureable disease at baseline.